Singulair (montelukast) Disease Interactions
There are 2 disease interactions with Singulair (montelukast):
Montelukast (Includes Singulair) ↔ liver disorder
Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease
Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis. Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast. No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency. The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated. Use caution when prescribing montelukast to these patients.
Montelukast (Includes Singulair) ↔ PKU
Moderate Potential Hazard, Moderate plausibility. Applies to: Phenylketonuria
Singulair (brand of montelukast) chewable tablets contain 0.842 mg of phenylalanine per each 5 mg tablet. The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).
- "Product Information. Singulair (montelukast)." Merck & Co, Inc, West Point, PA.
Singulair (montelukast) drug interactions
There are 88 drug interactions with Singulair (montelukast)
More about Singulair (montelukast)
- Singulair Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Patient Tips
- Drug Images
- Drug Interactions
- Compare Alternatives
- Support Group
- Pricing & Coupons
- En Español
- 144 Reviews
- Generic Availability
- Drug class: leukotriene modifiers
- FDA Alerts (2)
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.